Vaxart, Inc.

Vaxart is excited to present research featuring its COVID-19 and norovirus oral pill vaccine candidates at the The World Vaccine Congress taking place October 28-31, 2024, in Barcelona. James Cummings will present a clinical update on our oral vaccine candidate and Sean Tucker will present data on how our oral norovirus vaccine candidate induces cross-reactivity and clinical data on protection against infection in humans. Read more about our upcoming presentations here: https://lnkd.in/evYBKsgh #WVCEU #VaccineDevelopment #pillthatmovestheneedle #norovirus #COVID-19

We are excited to present research demonstrating the potential of our norovirus oral pill vaccine candidate at IDWeek taking place October 16-19, 2024, at the Los Angeles Convention Center.   Sean Tucker and Lam Nguyen, M.D. will each present our clinical research from our Phase 2 challenge study and Phase 1 trial focused on lactating mothers, respectively, underscoring our commitment to this serious unmet need.   Read more about our upcoming presentations here https://lnkd.in/emHasJ8B   #pillthatmovestheneedle #norovirus

Vaxart celebrates #IndigenousPeoplesDay and the rich histories, cultures, and contributions of Indigenous communities. We support building a future that respects and uplifts Indigenous peoples and their voices. #CulturalHeritage #Inclusion #Vaxart #PillThatMovesTheNeedle

We are excited to announce that the first participant has been dosed in the sentinel cohort of a Phase 2b study evaluating our COVID-19 oral pill vaccine candidate against an mRNA comparator.   The 400-participant sentinel cohort is funded as part of Project NextGen, an initiative led by Biomedical Advanced Research and Development Authority (BARDA) and National Institute of Allergy and Infectious Diseases (NIAID), with the trial valued at up to $456 million.   The sentinel portion of Phase 2b study will evaluate the safety, immunogenicity and efficacy of Vaxart’s next generation oral pill COVID-19 vaccine compared to an approved mRNA vaccine comparator.   Upon review of the safety data, the trial will proceed to enroll 10,000 additional participants.   Read more in our press release that we issued last week: https://lnkd.in/eFv3fKcN   #PillThatMovesTheNeedle #COVID19 #BARDA #NIAID #vaccines #globalhealth

Our CMO, James Cummings, discussed our innovative COVID-19 platform in a two-part interview with Contagion_Live. During the interview, Dr. Cummings highlighted our recently initiated COVID-19 Phase 2b study under Project NextGen, the benefits of our oral vaccine in potentially enhancing immune response and our goal of transforming public health. Part 1: https://lnkd.in/d5Kneb4k Part 2: https://lnkd.in/e73jYQXb

Our partner Vaxart, Inc. announced the initiation of the sentinel cohort of its Phase 2b clinical trial, which aims to determine the efficacy, safety, and immunogenicity of Vaxart’s oral COVID-19 vaccine candidate compared to a traditional, FDA-approved vaccine. This effort is a part of overarching work supported under #ProjectNextGen to create vaccines that work better than those currently available. Earlier this year, we announced the initial work with Vaxart, along with other partners, to plan and execute multiple Phase 2b clinical trials. Learn more about our efforts to protect Americans against COVID-19: https://ow.ly/vz0a50Tzvc8

Today, we announced the initiation of the sentinel cohort of our Phase 2b clinical trial evaluating the safety, immunogenicity and efficacy of Vaxart’s next generation oral pill COVID-19 vaccine candidate against an approved mRNA vaccine comparator. The sentinel cohort, for which funding is now approved, is being funded as part of the Phase 2b NextGen COVID-19 clinical trial, valued at up to $456 million through the RRPV | Rapid Response Partnership Vehicle under the U.S. government’s Project NextGen. Read more in our press release here: https://lnkd.in/eFv3fKcN #PillThatMovesTheNeedle #COVID19 #BARDA #vaccines #globalhealth

In case you missed it, preclinical data published last week in Vaccines MDPI demonstrated the therapeutic potential of Vaxart’s mucosal vaccine technology platform. These data show that Vaxart’s HPV vaccine constructs stimulate specific T cell immune responses, reduce tumor size, and increase survival in an animal model of HPV-related tumorigenesis. Results also suggest that Vaxart’s mucosal vaccine platform holds promise in enabling a novel, non-invasive treatment for HPV-related cervical dysplasia. Read more in our press release here: https://t.co/Zb61JqnVqD

Happy Labor Day! Vaxart celebrates the incredible contributions of workers across all industries. Their commitment and drive are the backbone of innovation and progress. Here’s to the value of teamwork, perseverance, and the pursuit of excellence — thank you for your dedication! #LaborDay #Freedom #Vaxart #PillThatMovesTheNeedle

We are excited to share published preclinical data demonstrating the potential of our mucosal vaccine technology platform in enabling therapeutic vaccination against HPV-related cervical dysplasia in the current issue of Vaccines MDPI. “The preclinical data published in Vaccines demonstrate that our mucosal vaccines stimulate T cells to destroy HPV-expressing cells, reducing the size of HPV-derived tumors and increasing the survival of mice bearing these tumors,” said Sean Tucker, Vaxart’s Founder and Chief Scientific Officer. Read more in today’s press release: https://bit.ly/476Tw9y